CX3CL1 promotes breast cancer via transactivation of the EGF pathway.

Chemokines are relevant molecules in shaping the tumor microenvironment, although their contributions to tumorigenesis are not fully understood. We studied the influence of the chemokine CX3CL1/fractalkine in de novo breast cancer formation using HER2/neu transgenic mice. CX3CL1 expression was downmodulated in HER2/neu tumors, yet, paradoxically, adenovirus-mediated CX3CL1 expression in the tumor milieu enhanced mammary tumor numbers in a dose-dependent manner. Increased tumor multiplicity was not a consequence of CX3CL1-induced metastatic dissemination of the primary tumor, although CX3CL1 induced epithelial-to-mesenchymal transition in breast cancer cells in vitro. Instead, CX3CL1 triggered cell proliferation by induction of ErbB receptors through the proteolytic shedding of an ErbB ligand. This effect was important insofar as mammary tumorigenesis was delayed and tumor multiplicity was reduced by genetic deletion of CX3CL1 in HER2/neu mice, but not in polyoma middle T-antigen oncomice. Our findings support the conclusion that CX3CL1 acts as a positive modifier of breast cancer in concert with ErbB receptors.

[1]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[2]  A. Ullrich,et al.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.

[3]  A. Schulze,et al.  Analysis of the transcriptional program induced by Raf in epithelial cells , 2001, Nature Genetics.

[4]  Yosef Yarden,et al.  Feedback regulation of EGFR signalling: decision making by early and delayed loops , 2011, Nature Reviews Molecular Cell Biology.

[5]  P. Allavena,et al.  Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. , 2010, European journal of cancer.

[6]  L. Coussens,et al.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity , 2010, Cancer and Metastasis Reviews.

[7]  V. Quesada,et al.  Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. , 2009, The Journal of clinical investigation.

[8]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[9]  Lucila Ohno-Machado,et al.  Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. , 2011, Cancer research.

[10]  Steffen Jung,et al.  In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. , 2011, Blood.

[11]  R. Cardiff,et al.  Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression , 2003, Oncogene.

[12]  D. Greaves,et al.  Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling , 2009, Cardiovascular research.

[13]  Timothy Hunter,et al.  Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer , 2009, Breast Cancer Research and Treatment.

[14]  L. Zitvogel,et al.  Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. , 2010, Cancer research.

[15]  S. Shimizu,et al.  CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. , 2008, Cancer research.

[16]  M. Maa,et al.  c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.

[17]  Keigo Nishida,et al.  Gab1 Acts as an Adapter Molecule Linking the Cytokine Receptor gp130 to ERK Mitogen-Activated Protein Kinase , 1998, Molecular and Cellular Biology.

[18]  R. Chadwick,et al.  EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines , 2004, Breast Cancer Research and Treatment.

[19]  W. Muller,et al.  Signal Transduction in Transgenic Mouse Models of Human Breast Cancer—Implications for Human Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[20]  A. Ullrich,et al.  EGFR signal transactivation in cancer cells. , 2003, Biochemical Society transactions.

[21]  S. Lira,et al.  Generation and Analysis of Mice Lacking the Chemokine Fractalkine , 2001, Molecular and Cellular Biology.

[22]  B. Cambien,et al.  Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer , 2006, Gut.

[23]  C. Tanikawa,et al.  Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. , 2000, Cancer research.

[24]  N. Harpaz,et al.  A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. , 2012, Gastroenterology.

[25]  Robert D. Cardiff,et al.  Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.

[26]  Haiyan I. Li,et al.  Purification and unique properties of mammary epithelial stem cells , 2006, Nature.

[27]  P. Hu,et al.  Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma , 2007, Gene Therapy.

[28]  K. Harshman,et al.  CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner , 2003, The Journal of experimental medicine.

[29]  Manuel A. González,et al.  A role for chemokine receptor transactivation in growth factor signaling , 2001, EMBO reports.

[30]  C. Combadière,et al.  Identification of the Chemokine CX3CL1 as a New Regulator of Malignant Cell Proliferation in Epithelial Ovarian Cancer , 2011, PloS one.

[31]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[32]  J. Baselga,et al.  p95HER2 and breast cancer. , 2011, Cancer research.

[33]  Walter Kolch,et al.  Cell fate decisions are specified by the dynamic ERK interactome , 2009, Nature Cell Biology.

[34]  Juan Pablo Albar,et al.  Type I phosphatidylinositol 4-phosphate 5-kinase controls neutrophil polarity and directional movement , 2007, The Journal of cell biology.

[35]  M. Bissell,et al.  An “elite hacker” , 2012, Cell adhesion & migration.

[36]  P. Rodriguez-Viciana,et al.  Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control , 2006, Proceedings of the National Academy of Sciences.

[37]  Y. Yarden,et al.  p38 MAP kinase mediates stress‐induced internalization of EGFR: implications for cancer chemotherapy , 2006, The EMBO journal.

[38]  F. Balkwill.  The chemokine system and cancer , 2012, The Journal of pathology.

[39]  C. Liebmann.  EGF receptor activation by GPCRs: An universal pathway reveals different versions , 2011, Molecular and Cellular Endocrinology.

[40]  A. Ashworth,et al.  CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells , 2005, Breast Cancer Research.

[41]  Alicia González-Martín,et al.  Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. , 2011, Cancer research.

[42]  H. Ford,et al.  Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity , 2011, Breast Cancer Research.

[43]  Yong Wang,et al.  Systemic dissemination of viral vectors during intratumoral injection. , 2003, Molecular cancer therapeutics.

[44]  Renee Rubio,et al.  Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue , 2009, Breast Cancer Research and Treatment.

[45]  K. Horwitz,et al.  Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. , 2006, Cancer research.

[46]  Steffen Jung,et al.  Control of microglial neurotoxicity by the fractalkine receptor , 2006, Nature Neuroscience.

[47]  Taoyong Chen,et al.  Fractalkine transgene induces T‐cell‐dependent antitumor immunity through chemoattraction and activation of dendritic cells , 2003, International journal of cancer.

[48]  P. Debré,et al.  Fractalkine mediates natural killer-dependent antitumor responses in vivo. , 2003, Cancer research.

[49]  Jonathan Melamed,et al.  Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence , 2008, Cell.